|
1
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: the BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Villanueva A, Hernandez-Gea V and Llovet
JM: Medical therapies for hepatocellular carcinoma: a critical view
of the evidence. Nat Rev Gastroenterol Hepatol. 10:34–42. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J and Sherman M; American
Association for the Study of Liver Diseases. Management of
hepatocellular carcinoma: an update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
European Association for the Study of the
Liver; European Organisation for Research and Treatment of Cancer.
EASL-EORTC clinical practice guidelines: management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012.PubMed/NCBI
|
|
5
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng AL, Kang YK, Chen Z, et al: Efficacy
and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.
2009. View Article : Google Scholar
|
|
7
|
Abou-Alfa GK, Amadori D, Santoro A, et al:
Safety and efficacy of sorafenib in patients with hepatocellular
carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest
Cancer Res. 4:40–44. 2011.PubMed/NCBI
|
|
8
|
Chiu J, Tang YF, Yao TJ, et al: The use of
single-agent sorafenib in the treatment of advanced hepatocellular
carcinoma patients with underlying Child-Pugh B liver cirrhosis: a
retrospective analysis of efficacy, safety, and survival benefits.
Cancer. 118:5293–5301. 2012. View Article : Google Scholar
|
|
9
|
Kim HY, Park JW, Joo J, et al: Worse
outcome of sorafenib therapy associated with ascites and Child-Pugh
score in advanced hepatocellular carcinoma. J Gastroenterol
Hepatol. 28:1756–1761. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pressiani T, Boni C, Rimassa L, et al:
Sorafenib in patients with Child-Pugh class A and B advanced
hepatocellular carcinoma: a prospective feasibility analysis. Ann
Oncol. 24:406–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu AX: Systemic therapy of advanced
hepatocellular carcinoma: how hopeful should we be? Oncologist.
11:790–800. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang TS, Chang HK, Chen JS, Lin YC, Liau
CT and Chang WC: Chemotherapy using 5-fluorouracil, mitoxantrone,
and cisplatin for patients with advanced hepatocellular carcinoma:
an analysis of 63 cases. J Gastroenterol. 39:362–369. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang KH, Lin CC and Yeh CT: GALNT14 SNP
as a potential predictor of response to combination chemotherapy
using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Pharmacogenomics. 12:1061–1073. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yeh CT, Chen HC, Sung CM, et al:
Retrospective comparison between a regular and a split-dose
protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the
treatment of far advanced hepatocellular carcinoma. BMC Cancer.
11:1172011. View Article : Google Scholar
|
|
15
|
Yeh CT, Liang KH, Lin CC, Chang ML, Hsu CL
and Hung CF: A single nucleotide polymorphism on the GALNT14 gene
as an effective predictor of response to chemotherapy in advanced
hepatocellular carcinoma. Int J Cancer. 134:1214–1224. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Trotti A, Colevas AD, Setser A, et al:
CTCAE v3.0: development of a comprehensive grading system for the
adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu C, Xiao GQ, Yan LN, et al: Value of
α-fetoprotein in association with clinicopathological features of
hepatocellular carcinoma. World J Gastroenterol. 19:1811–1819.
2013.
|
|
19
|
Tangkijvanich P1, Anukulkarnkusol N,
Suwangool P, et al: Clinical characteristics and prognosis of
hepatocellular carcinoma: analysis based on serum alpha-fetoprotein
levels. J Clin Gastroenterol. 31:302–308. 2000. View Article : Google Scholar
|
|
20
|
Ma WJ, Wang HY and Teng LS: Correlation
analysis of preoperative serum alpha-fetoprotein (AFP) level and
prognosis of hepatocellular carcinoma (HCC) after hepatectomy.
World J Surg Oncol. 11:2122013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang SK, Hlaing WW, Yu RQ, Lee TW,
Ganpathi IS and Madhavan KK: Value of alpha-foetoprotein for
screening of recurrence in hepatocellular carcinoma post resection.
Singapore Med J. 53:32–35. 2012.PubMed/NCBI
|
|
22
|
Lee YK, Kim SU, Kim do Y, et al:
Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin
responses in patients with hepatocellular carcinoma treated with
transarterial chemoembolization. BMC Cancer. 13:52013.
|
|
23
|
Personeni N, Bozzarelli S, Pressiani T, et
al: Usefulness of alpha-fetoprotein response in patients treated
with sorafenib for advanced hepatocellular carcinoma. J Hepatol.
57:101–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Memon K, Kulik L, Lewandowski RJ, et al:
Alpha-fetoprotein response correlates with EASL response and
survival in solitary hepatocellular carcinoma treated with
transarterial therapies: a subgroup analysis. J Hepatol.
56:1112–1120. 2012. View Article : Google Scholar
|
|
25
|
Lee MH, Kim SU, Kim do Y, et al: Early
on-treatment predictions of clinical outcomes using
alpha-fetoprotein and des-gamma-carboxy prothrombin responses in
patients with advanced hepatocellular carcinoma. J Gastroenterol
Hepatol. 27:313–322. 2012. View Article : Google Scholar
|
|
26
|
Nakazawa T, Hidaka H, Takada J, et al:
Early increase in α-fetoprotein for predicting unfavorable clinical
outcomes in patients with advanced hepatocellular carcinoma treated
with sorafenib. Eur J Gastroenterol Hepatol. 25:683–689. 2013.
|
|
27
|
Patt YZ, Yoffe B, Charnsangavej C, et al:
Low serum alpha-fetoprotein level in patients with hepatocellular
carcinoma as a predictor of response to 5-FU and
interferon-alpha-2b. Cancer. 72:2574–2582. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li MS, Ma QL, Chen Q, et al:
Alpha-fetoprotein triggers hepatoma cells escaping from immune
surveillance through altering the expression of Fas/FasL and tumor
necrosis factor related apoptosis-inducing ligand and its receptor
of lymphocytes and liver cancer cells. World J Gastroenterol.
11:2564–2569. 2005. View Article : Google Scholar
|
|
29
|
Iida H, Honda M, Kawai HF, et al:
Ephrin-A1 expression contributes to the malignant characteristics
of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut.
54:843–851. 2005.PubMed/NCBI
|
|
30
|
Lee CK, Simes RJ, Brown C, et al:
Prognostic nomogram to predict progression-free survival in
patients with platinum-sensitive recurrent ovarian cancer. Br J
Cancer. 105:1144–1150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shitara K, Matsuo K, Takahari D, et al:
Neutropenia as a prognostic factor in advanced gastric cancer
patients undergoing second-line chemotherapy with weekly
paclitaxel. Ann Oncol. 21:2403–2409. 2010. View Article : Google Scholar
|
|
32
|
Shitara K, Matsuo K, Takahari D, et al:
Neutropaenia as a prognostic factor in metastatic colorectal cancer
patients undergoing chemotherapy with first-line FOLFOX. Eur J
Cancer. 45:1757–1763. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pallis AG, Agelaki S, Kakolyris S, et al:
Chemotherapy-induced neutropenia as a prognostic factor in patients
with advanced non-small cell lung cancer treated with front-line
docetaxel-gemcitabine chemotherapy. Lung Cancer. 62:356–363. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koutras AK, Fountzilas G, Dafni U, et al;
Hellenic Cooperative Oncology Group. Myelotoxicity as a prognostic
factor in patients with advanced breast cancer treated with
chemotherapy: a pooled analysis of two randomised trials conducted
by the Hellenic Cooperative Oncology Group. Anticancer Res.
28:2913–2920. 2008.
|
|
35
|
Yamanaka T, Matsumoto S, Teramukai S,
Ishiwata R, Nagai Y and Fukushima M: Predictive value of
chemotherapy-induced neutropenia for the efficacy of oral
fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer.
97:37–42. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Di Maio M, Gridelli C, Gallo C, et al:
Chemotherapy-induced neutropenia and treatment efficacy in advanced
non-small-cell lung cancer: a pooled analysis of three randomised
trials. Lancet Oncol. 6:669–677. 2005.PubMed/NCBI
|
|
37
|
Poikonen P, Saarto T, Lundin J, Joensuu H
and Blomqvist C: Leucocyte nadir as a marker for chemotherapy
efficacy in node-positive breast cancer treated with adjuvant CMF.
Br J Cancer. 80:1763–1766. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Saarto T, Blomqvist C, Rissanen P, Auvinen
A and Elomaa I: Haematological toxicity: a marker of adjuvant
chemotherapy efficacy in stage II and III breast cancer. Br J
Cancer. 75:301–305. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shitara K, Matsuo K, Oze I, et al:
Meta-analysis of neutropenia or leukopenia as a prognostic factor
in patients with malignant disease undergoing chemotherapy. Cancer
Chemother Pharmacol. 68:301–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lagman RL, Davis MP, LeGrand SB and Walsh
D: Common symptoms in advanced cancer. Surg Clin North Am.
85:237–255. 2005. View Article : Google Scholar
|
